Current Opinion in Lipidology volume 26, issue 3, P188-194 2015 DOI: 10.1097/mol.0000000000000170 View full text
|
|
Share
Nadeem Qureshi, Rubin Minhas, Anthony S. Wierzbicki

Abstract: Modern systematic evidence assessment and economic appraisal convincingly favour the use of lipid-lowering drugs especially statins at higher doses than currently prescribed in secondary prevention and at lower risk thresholds in primary care than previously imagined. As long-term adherence to treatment is required patient choice is key to realizing the benefits of these interventions.